Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

NCT03724071 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

51

Enrollment

INDUSTRY

Sponsor class

Stopped Study has been terminated after Phase I part on 23 February 2023

Conditions

Colorectal Neoplasm
Digestive System Neoplasm

Interventions

BIOLOGICAL: TG6002
DRUG: Flucytosine (5-FC, Ancotil)

Sponsor

Transgene